Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 33 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

29Total
Not Applicable (7)
Early P 1 (2)
P 1 (9)
P 2 (11)

Trial Status

Recruiting16
Not Yet Recruiting15
Unknown1
Completed1

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 1 completed trials

Clinical Trials (33)

Showing 20 of 20 trials
NCT07842276Phase 2Not Yet RecruitingPrimary

Utidelone Capsules Combined With Doxorubicin for Advanced Soft Tissue Sarcoma

NCT07811297Phase 1Not Yet Recruiting

A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers

NCT07811232Phase 1Not Yet Recruiting

A Study of AL58805 in Advanced, Metastatic GYN, STS or Breast Cancers

NCT07801222Phase 1Not Yet Recruiting

A Study to Assess Safety and Efficacy of SOT106 in Patients With LRRC15-positive Advanced Unresectable or Metastatic Osteosarcoma or Soft Tissue Sarcoma

NCT07460986Phase 1RecruitingPrimary

A Phase Ib/II Study to Evaluate Safety and Efficacy of Bexmarilimab in Combination With Doxorubicin in Metastatic Soft-tissue Sarcoma.

NCT07630961Phase 1Recruiting

Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors

NCT07662239Not ApplicableRecruiting

Bridging Adolescent and Young Adult Sarcoma Survivors With Personalized Oncology Exercise Service (AYA-ONE): A Pilot Intervention

NCT07741877Phase 2Not Yet Recruiting

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Soft Tissue Sarcoma

NCT07729059Not ApplicableNot Yet Recruiting

"Exercise Intervention to Increase Physical Activity in Young Sarcoma Survivors (Sport Ist Herzenssache)"

NCT07038278Early Phase 1Not Yet RecruitingPrimary

5-AminoLevulinic Acid Aided Resection Margins in Sarcoma

NCT07650838Phase 2Not Yet RecruitingPrimary

OVV-01 Injection Combined With AK112 Injection for the Treatment of Patients With Advanced Soft Tissue Sarcoma (STS)

NCT07648069Phase 1RecruitingPrimary

Tumor Neoantigen Vaccine SarVac Combined With Tumor Specific Lymphocyte Reinfusion in the Treatment of Advanced Sarcoma

NCT06967961Not ApplicableRecruiting

Research of Double-positive Circulating Cells (Tumor Marker / CD45+) in Several Types of Metastatic Cancers

NCT07612098Phase 2Not Yet RecruitingPrimary

Preoperative Radiotherapy and Anlotinib With or Without Penpulimab for Soft Tissue Sarcoma

NCT07602049Phase 2RecruitingPrimary

Cryoablation Plus Camrelizumab for Advanced Soft Tissue Sarcoma

NCT06980259Not ApplicableRecruitingPrimary

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma

NCT06815666Phase 2RecruitingPrimary

BAL Fluid Biomarkers in Sarcoma

NCT07432932Recruiting

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT07396116Not ApplicableNot Yet RecruitingPrimary

Preoperative Hypofractionated RT + Immunotherapy & Surgery for Retroperitoneal Sarcoma (FUSION-02)

NCT07173972Phase 2RecruitingPrimary

Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.

Scroll to load more

Research Network

Activity Timeline